Resmed Stock Price, News & Analysis

Resmed (NYSE: RMD) announced groundbreaking research published in The Lancet Respiratory Medicine showing that CPAP therapy significantly reduces mortality risk in sleep apnea patients. The largest-ever meta-analysis, analyzing over 1 million patients across 30 studies, revealed that CPAP users have a 37% lower risk of all-cause mortality and a 55% lower risk of cardiovascular-related death compared to non-users.

The study demonstrates a dose-response relationship, indicating greater survival benefits with more consistent CPAP use. This research included data from 10 randomized controlled trials and 20 real-world evidence studies, with an average follow-up period of nearly five years.

The findings are particularly significant given that obstructive sleep apnea (OSA) affects over one billion people worldwide, with more than 80% of cases remaining undiagnosed and untreated. The study establishes CPAP therapy as a life-saving intervention that requires only air, without drugs or surgery.

Resmed (NYSE: RMD, ASX: RMD) announced a comprehensive brand evolution to unify its portfolio under a single identity, marking a significant shift in its 35-year history. The health technology company, focused on sleep, breathing, and home care, aims to consolidate its brands, products, and services over the next couple of years.

The rebranding includes a new visual identity, logo, and brand voice, positioning Resmed as an approachable health technology leader. This evolution coincides with three major initiatives: a U.S. consumer campaign to destigmatize CPAP therapy, a primary care physician education campaign for earlier sleep apnea diagnosis, and a sleep health awareness campaign in Asia Pacific and Europe.

According to Resmed's 2025 Global Sleep Survey, one-third of respondents report sleep difficulties, with 34% having trouble falling asleep and 29% staying asleep. The company estimates that over 2.3 billion people worldwide suffer from sleep apnea, insomnia, COPD, or other respiratory insufficiency.

ResMed's fifth annual Global Sleep Survey of 30,026 people across 13 markets reveals a concerning global sleep crisis. People are losing nearly three nights of restorative sleep weekly, with one-third of respondents reporting sleep difficulties three or more times per week.

Key findings show that 71% of employed respondents have called in sick due to poor sleep, with highest rates in India (94%). About 18% of couples opt for 'sleep divorce' due to snoring and restlessness. Women experience poorer sleep quality than men (3.83 vs 4.13 quality nights per week).

The survey identifies primary sleep disruptors as stress (57%), anxiety (46%), and financial pressures (31%). Despite 89% believing sleep improves their well-being, only 24% would take immediate action to address sleep issues. Notably, 22% globally choose to 'just live with' poor sleep, reaching 41% in Australia.

ResMed (NYSE: RMD) reported strong Q2 FY2025 financial results with significant growth across key metrics. Revenue increased 10% to $1.3 billion, while operating profit surged 52% to $417.2 million. The company achieved notable margin improvements, with gross margin expanding 300 basis points to 58.6%.

Key highlights include operating cash flow of $309 million and diluted earnings per share of $2.34. The company's growth was driven by increased demand for sleep health and breathing products, along with digital health solutions. During the quarter, ResMed paid $78 million in dividends and repurchased 307,000 shares for $75 million.

The board declared a quarterly cash dividend of $0.53 per share, payable on March 20, 2025, to shareholders of record as of February 13, 2025.

ResMed (NYSE: RMD, ASX: RMD) has announced plans to release its second quarter fiscal 2025 financial and operational results on Thursday, January 30, 2025, after the New York Stock Exchange market close. The company will follow the release with a management-hosted webcast to discuss the quarterly results.

ResMed (NYSE: RMD, ASX: RMD) has announced that Mick Farrell, chairman and CEO, and Dr. Carlos Nunez, chief medical officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Monday, January 13, 2025, at approximately 3:00 p.m. (Pacific Standard Time) in San Francisco, CA.

The company will provide an audio-only webcast of the presentation, which can be accessed through the investor relations section of ResMed's website. A replay of the webcast will be available for 30 days following the live presentation.

Avant Technologies has entered a joint venture with Ainnova Tech to form Ai-nova Acquisition Corp (AAC), focusing on AI-powered healthcare solutions. The partnership will commercialize Ainnova's VisionAI platform and retinal cameras in North America and Europe. VisionAI can detect diabetic retinopathy and other diseases through retinal scans with high accuracy. With the global healthcare AI market projected to reach $188 billion by 2030, this venture aims to make retinal scanning a standard in primary care. The technology addresses a critical need, as 30% of 500 million diabetics globally may develop diabetic retinopathy, while there's a shortage of ophthalmologists.

ResMed (NYSE: RMD, ASX: RMD) announced that Chairman and CEO Mick Farrell and Chief Medical Officer Dr. Carlos Nunez will participate in a fireside chat at the UBS Global Healthcare Conference. The event will take place on November 12, 2024, at 3:30 p.m. PST at the Terranea Resort Hotel in Rancho Palos Verdes, CA. A live audio-only webcast will be available on the investor relations website, with a replay accessible for 30 days following the event.

ResMed reported strong Q1 FY2025 results with 11% year-over-year revenue growth to $1.2 billion. The company achieved significant improvements in profitability with operating profit up 34% and non-GAAP operating profit increasing 27%. Gross margin improved 420 basis points to 58.6%, while operating cash flow reached $326 million. Diluted earnings per share grew to $2.11, with non-GAAP EPS at $2.20. Growth was driven by increased demand for sleep devices and masks, along with strong performance in the Residential Care Software business. The company declared a quarterly dividend of $0.53 per share.